Skip to content
Triangle logo TriangleGet started
← Study library

NCT00651261 · CITED IN SOURCE DOCUMENTS

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
UNKNOWN
Registry last update
2021-08-18

The purpose of this study is to compare the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined with or without midostaurin (also known as PKC412), to find out which is better. This research is being done because it is unknown whether the addition of midostaurin to chemotherapy treatment is better than chemotherapy treatment alone. Midostaurin has been tested in over 400 patients and is being studied in a number of illnesses, including AML, colon cancer, and lung cancer. Midostaurin blocks an enzyme, produced by a gene known as FLT3, that may have a role in the survival and growth of AML cells. Not all leukemia cells will have the abnormal FLT3 gene. This study will focus only on patients with leukemia cells with the abnormal FLT3 gene.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Event- Free Survival

→

outcome · POSTED

Overall Survival, Censoring Participants Who Receive a Stem Cell Transplant at the Time of the Transplant

→

outcome · POSTED

Complete Response Rate

→

outcome · POSTED

Disease-free Survival (DFS)

→

outcome · NOT POSTED

DFS Rate One Year After Completing the Planned Continuation Phase

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
1. Documentation of Disease: * Unequivocal diagnosis of AML ( \> 20% blasts in the bone marrow based on the WHO classification), excluding M3 (acute promyelocytic leukemia). Patients with neurologic symptoms suggestive of CNS leukemia are recommended to have a lumbar puncture. Patients whose CSF is positive for AML blasts are not eligible. * Documented FLT3 mutation (ITD or point mutation), determined by analysis in a protocol- designated FLT3 screening laboratory. 2. Age Requirement: * Age ≥ 18 and \< 60 years 3. Prior Therapy: * No prior chemotherapy for leukemia or myelodysplasia with the following exceptions: * emergency leukapheresis * emergency treatment for hyperleukocytosis with hydroxyurea for ≤ 5 days * cranial RT for CNS leukostasis (one dose only) * growth factor/cytokine support * AML patients with a history of antecedent myelodysplasia (MDS) remain eligible for treatment on this trial, but must not have had prior cytotoxic therapy (e.g., azacitidine or decitabine) * Patients who have developed therapy related AML after prior RT or chemotherapy for another cancer or disorder are not eligible. 4. Cardiac Function: Patients with symptomatic congestive heart failure are not eligible. 5. Initial Laboratory Value: Total bilirubin \< 2.5 x ULN (Upper Limit of Normal) 6. Pregnancy and Nursing Status: * Non-pregnant and non-nursing due to the unknown teratogenic potential of midostaurin in humans, pregnant or nursing patients may not be enrolled. * Women of childbearing potential must have a negative serum or urine pregnancy test within a sensitivity of at least 50 mIU/mL within 16 days prior to registration. * Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or commit to TWO acceptable methods of birth control: * one highly effective method (eg, IUD, hormonal (non-oral contraceptive), tubal ligation, or partner's vasectomy) and * one additional effective method (e.g., latex condom, diaphragm or cervical cap) * The two acceptable methods of birth control must be used AT THE SAME TIME, before beginning midostaurin/placebo therapy and continuing for 12 weeks after completion of all therapy. * Note that oral contraceptives are not considered a high effective method because of the possibility of a drug interaction with midostaurin. * Women of childbearing potential is defined as a sexually active mature woman who has not undergone a hysterectomy or who has not had menses at any time in the preceding 24 consecutive months. * Men must agree not to father a child and must use a latex condom during any sexual contact with women of childbearing potential while taking midostaurin/placebo and for 12 weeks after therapy is stopped, even if they have undergone a successful vasectomy.
healthy Volunteers
false
maximum Age
59 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with midostaurin for twelve (12) months.
    intervention Names
    1. Drug: cytarabine
    2. Drug: daunorubicin
    3. Drug: midostaurin
    4. Drug: dexamethasone acetate
    label
    Induction and consolidation chemotherapy plus midostaurin
    type
    EXPERIMENTAL
  2. description
    Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and placebo. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with placebo. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with placebo for twelve (12) months.
    intervention Names
    1. Drug: cytarabine
    2. Drug: daunorubicin
    3. Other: placebo
    4. Drug: dexamethasone acetate
    label
    Induction and consolidation chemotherapy plus placebo
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. Induction and consolidation chemotherapy plus midostaurin
    2. Induction and consolidation chemotherapy plus placebo
    description
    Given IV
    name
    cytarabine
    type
    DRUG
  2. arm Group Labels
    1. Induction and consolidation chemotherapy plus midostaurin
    2. Induction and consolidation chemotherapy plus placebo
    description
    Given IV
    name
    daunorubicin
    type
    DRUG
  3. arm Group Labels
    1. Induction and consolidation chemotherapy plus midostaurin
    description
    Given orally
    name
    midostaurin
    type
    DRUG
  4. arm Group Labels
    1. Induction and consolidation chemotherapy plus placebo
    description
    Given orally
    name
    placebo
    type
    OTHER
  5. arm Group Labels
    1. Induction and consolidation chemotherapy plus midostaurin
    2. Induction and consolidation chemotherapy plus placebo
    description
    ocular medication administration
    name
    dexamethasone acetate
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
DOUBLE
who Masked
  1. PARTICIPANT
  2. INVESTIGATOR
primary Purpose
TREATMENT
Enrollment
count
717
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Overall survival (OS) was defined as the time interval from randomization to death from any cause. The median OS with 95% CI was estimated using the Kaplan-Meier method.
    measure
    Overall Survival (OS)
    time Frame
    Duration of study (Up to 10 years)
secondary Outcomes
  1. description
    Event free survival (EFS) was defined as the time from randomization until the earliest qualifying event, including: failure to obtain a CR on or before 60 days of initiation of protocol therapy; relapse; or death from any cause. Patients alive and event free at the time of analysis were censored on the date of last clinical assessment. The median EFS with 95% CI was estimated using the Kaplan-Meier method. Due to a higher than expected transplant rate, EFS was promoted to be a key secondary endpoint.
    measure
    Event- Free Survival
    time Frame
    Duration of study (Up to 10 years)
  2. description
    Overall survival (OS) was defined as the time interval from randomization to death from any cause. Any participants who received a stem cell transplant were censored at the time of transplant. The median OS with 95% CI was estimated using the Kaplan-Meier method.
    measure
    Overall Survival, Censoring Participants Who Receive a Stem Cell Transplant at the Time of the Transplant
    time Frame
    Duration of study (Up to 10 years)
  3. description
    Percentage of participants who achieved a complete response (CR). A CR was defined as normalization of blood counts and a marrow showing less than 5% blasts occurring on or before day 60.
    measure
    Complete Response Rate
    time Frame
    Induction therapy (up to 60 days)
  4. description
    Disease free survival (DFS) is defined as the time from documentation of first CR at any time to the first of relapse or death from any cause in participants who achieved a CR.
    measure
    Disease-free Survival (DFS)
    time Frame
    Duration of study (Up to 10 years)
  5. measure
    DFS Rate One Year After Completing the Planned Continuation Phase
    time Frame
    30 months
Full study description
brief Summary
The purpose of this study is to compare the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined with or without midostaurin (also known as PKC412), to find out which is better. This research is being done because it is unknown whether the addition of midostaurin to chemotherapy treatment is better than chemotherapy treatment alone. Midostaurin has been tested in over 400 patients and is being studied in a number of illnesses, including AML, colon cancer, and lung cancer. Midostaurin blocks an enzyme, produced by a gene known as FLT3, that may have a role in the survival and growth of AML cells. Not all leukemia cells will have the abnormal FLT3 gene. This study will focus only on patients with leukemia cells with the abnormal FLT3 gene.
detailed Description
In this study, patients will receive either the experimental agent (midostaurin) or placebo combined with chemotherapy treatment. Patients are stratified according to FLT3 mutation status (internal tandem duplication \[ITD\] allelic ratio \< 0.7 vs ITD allelic ratio ≥ 0.7 vs tandem kinase domain \[TKD\]). There are three parts to the study treatment: remission induction therapy, remission consolidation therapy and continuation therapy. Remission Induction Therapy: * Cytarabine 200 mg/m2/day by continuous intravenous infusion on days 1-7 * Daunorubicin 60 mg/m2/day by intravenous push or short infusion on days 1-3 * Midostaurin 50 mg (two 25 mg capsules) or placebo for midostaurin (2 capsules) twice a day by mouth on days 8-21 * A bone marrow aspiration will be performed in all patients on Day 21 to determine the need for a second induction cycle. Remission Consolidation (Four Remission Consolidation Cycles): * High dose cytarabine 3000 mg/m2 will be given by intravenous infusion over 3 hours every 12 hours on days 1, 3 and 5. Serial neurologic evaluation will be performed before and following the infusion of high-dose cytarabine. * Dexamethasone 0.1% or other corticosteroid ophthalmic solution 2 drops to each eye once daily to begin 6-12 hours prior to the initiation of the cytarabine infusion and to continue for at least 24 hours after the last cytarabine dose. * Midostaurin 50 mg (two 25 mg capsules) or placebo for midostaurin (2 capsules) twice a day by mouth on days 8-21 Midostaurin/Placebo Continuation Therapy: * Midostaurin 50 mg (two 25 mg capsules) or placebo for midostaurin (2 capsules) by mouth twice a day for 28 days. Each cycle will be 28 days in length. Continuation therapy with midostaurin/placebo will continue until relapse or for 12 cycles maximum. The primary and secondary objectives of this study are: Primary objective: * To determine if the addition of midostaurin to daunorubicin/cytarabine induction, high-dose cytarabine consolidation, and continuation therapy improves overall survival (OS) in both the mutant FLT3-ITD and FLT3-TKD AML patients Secondary objectives: * To compare the overall survival (OS) in the two groups using an analysis in which patients who receive a stem cell transplant are censored at the time of transplant * To compare the complete response (CR) rate between the two treatment groups * To compare the event-free survival (EFS) between the two treatment groups * To compare the disease free survival (DFS) of the two treatment groups * To compare the disease free survival rate one year after completion of the continuation phase of the two groups * To assess the toxicity of the experimental combination * To describe the interaction between treatment outcome and pretreatment characteristics such as age, performance status, white blood cell (WBC) count, morphology, cytogenetics, and molecular and pharmacodynamic features * To assess the population pharmacokinetics (popPK) of midostaurin and its two major metabolites (CGP52421 and CGP62221). The potential association(s) between PK exposure and FLT3 status, OS, EFS and clinical response will be explored There is a pharmacokinetic sub-study (CALGB 60706) within CALGB 10603. This embedded companion study must be offered to all patients enrolled on CALGB 10603, although patients may opt not to participate in CALGB 60706. After study entry, patients are followed periodically for up to 10 years.
Source references
references
  1. citation
    Stone RM, Dohner H, Ehninger G, et al.: CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML. [Abstract] J Clin Oncol 29 (Suppl 15): A-TPS199, 2011.
    type
    RESULT
  2. citation
    Seffernick AE, Mrozek K, Nicolet D, Stone RM, Eisfeld AK, Byrd JC, Archer KJ. High-dimensional genomic feature selection with the ordered stereotype logit model. Brief Bioinform. 2022 Nov 19;23(6):bbac414. doi: 10.1093/bib/bbac414.
    pmid
    36184192
    type
    DERIVED
  3. citation
    Voso MT, Larson RA, Jones D, Marcucci G, Prior T, Krauter J, Heuser M, Lavorgna S, Nomdedeu J, Geyer SM, Walker A, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte TM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen Y, Pallaud C, Du L, Piciocchi A, Ehninger G, Byrd J, Thiede C, Dohner K, Stone RM, Dohner H, Bloomfield CD, Lo-Coco F. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv. 2020 Oct 13;4(19):4945-4954. doi: 10.1182/bloodadvances.2020002904.
    pmid
    33049054
    type
    DERIVED
  4. citation
    Walker CJ, Kohlschmidt J, Eisfeld AK, Mrozek K, Liyanarachchi S, Song C, Nicolet D, Blachly JS, Bill M, Papaioannou D, Oakes CC, Giacopelli B, Genutis LK, Maharry SE, Orwick S, Archer KJ, Powell BL, Kolitz JE, Uy GL, Wang ES, Carroll AJ, Stone RM, Byrd JC, de la Chapelle A, Bloomfield CD. Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. Clin Cancer Res. 2019 Nov 1;25(21):6524-6531. doi: 10.1158/1078-0432.CCR-19-0725. Epub 2019 Aug 2.
    pmid
    31375516
    type
    DERIVED
  5. citation
    Yin J, LaPlant B, Uy GL, Marcucci G, Blum W, Larson RA, Stone RM, Mandrekar SJ. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019 Jun 11;3(11):1714-1721. doi: 10.1182/bloodadvances.2018026112.
    pmid
    31171508
    type
    DERIVED
  6. citation
    Stein E, Xie J, Duchesneau E, Bhattacharyya S, Vudumula U, Ndife B, Bonifacio G, Guerin A, Li N, Joseph G. Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States. Pharmacoeconomics. 2019 Feb;37(2):239-253. doi: 10.1007/s40273-018-0732-4.
    pmid
    30382485
    type
    DERIVED
  7. citation
    Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Dohner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Dohner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.
    pmid
    28644114
    type
    DERIVED
  8. citation
    Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, DeAngelo DJ, Huntsman-Labed A, Dutreix C, del Corral A, Giles F. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012 Sep;26(9):2061-8. doi: 10.1038/leu.2012.115. Epub 2012 Apr 27.
    pmid
    22627678
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-4c57ceab1599f8cc085d
      requested nct id
      NCT00651261
      primary nct id
      NCT00651261
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      34fd1fb9f30a06b79415d02c9e1ed422ade2f4bc02b2c78ec5acbb31f3ab7575
      payload sha256
      160dd84ac6c9b60791ba690d055cfa928da8d32433295a86a769d8db8c823d00
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-4c57ceab1599f8cc085d
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00651261
      occurrences
      1. context exact
        1">Evidence (midostaurin):</p> <div class="pdq-content-list"><ol id="_805"><li>A multicenter, randomized, phase III trial (<a href="/clinicaltrials/NCT00651261">NCT00651261</a>) included patients with <em class="gene-name">FLT3</em>-altered AML. Patients received either the FLT3/multikinase inhibitor, midostaurin, or
        end
        153683
        exact text
        NCT00651261
        start
        153672
      2. context exact
        midostaurin):</p> <div class="pdq-content-list"><ol id="_805"><li>A multicenter, randomized, phase III trial (<a href="/clinicaltrials/NCT00651261">NCT00651261</a>) included patients with <em class="gene-name">FLT3</em>-altered AML. Patients received either the FLT3/multikinase inhibitor, midostaurin, or placebo in ad
        end
        153696
        exact text
        NCT00651261
        start
        153685
      3. context exact
        ciated with an inferior outcome.</p> <div class="pdq-content-list"><ol id="_665"><li>In the multicenter, randomized, phase III <a href="/clinicaltrials/NCT00651261">RATIFY</a> trial (NCT00651261), the FLT3/multikinase inhibitor midostaurin plus cytarabine and daunorubicin induction chemotherapy was compared with placebo i
        end
        197404
        exact text
        NCT00651261
        start
        197393
      4. context exact
        .</p> <div class="pdq-content-list"><ol id="_665"><li>In the multicenter, randomized, phase III <a href="/clinicaltrials/NCT00651261">RATIFY</a> trial (NCT00651261), the FLT3/multikinase inhibitor midostaurin plus cytarabine and daunorubicin induction chemotherapy was compared with placebo in patients with <em class="gene
        end
        197435
        exact text
        NCT00651261
        start
        197424
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/18d2b12fbb5f0650e6.html
      source file sha256
      34fd1fb9f30a06b79415d02c9e1ed422ade2f4bc02b2c78ec5acbb31f3ab7575
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:53.074610+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      454d4af27284fdd87ef57958565fbfaa1f8cabea4d6a7515759997a5fb0fc65e
      source title
      Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: March 14, 2025
        datetime
        2025-03-14T12:00:00Z
        display
        March 14, 2025
    2. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-61c0dfbf14d3fe0ad1c9
      requested nct id
      NCT00651261
      primary nct id
      NCT00651261
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      8e7cc2e32fc51992c491e61751eea5c12733e2487675051b006bf5d81066b2f7
      payload sha256
      69347940a2f08a4a653b46a5133e3803c03748d379cd140172dbe785fcf89e64
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-61c0dfbf14d3fe0ad1c9
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00651261
      occurrences
      1. context exact
        h de novo AML):</p> <div class="pdq-content-list"><ol id="_1954"><li>In a randomized, placebo-controlled, phase III study (<a href="/clinicaltrials/NCT00651261">CALGB10603/RATIFY [NCT00651261]</a>) of 717 adults aged 18 to 59 years with AML and <em class="gene-name">FLT3</em> ITD or TKD variants, standard chemotherapy
        end
        364474
        exact text
        NCT00651261
        start
        364463
      2. context exact
        <div class="pdq-content-list"><ol id="_1954"><li>In a randomized, placebo-controlled, phase III study (<a href="/clinicaltrials/NCT00651261">CALGB10603/RATIFY [NCT00651261]</a>) of 717 adults aged 18 to 59 years with AML and <em class="gene-name">FLT3</em> ITD or TKD variants, standard chemotherapy was given with or without midos
        end
        364506
        exact text
        NCT00651261
        start
        364495
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/73204a34a100b0fa2e.html
      source file sha256
      8e7cc2e32fc51992c491e61751eea5c12733e2487675051b006bf5d81066b2f7
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:53.537755+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      74fb97edc9145215f8b85c366e8cc116f08a5151772cf550992345b297a46bf0
      source title
      Childhood Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: April 15, 2025
        datetime
        2025-04-15T12:00:00Z
        display
        April 15, 2025

    Preserved source evidence · Not medical advice